Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Byo Holdings LLC has 2 pending office actions currently active in the Biotechnology & Pharmaceuticals technology area. These actions are being handled by 2 distinct examiners, though they are both located within 1 distinct art unit. This concentration in 1 distinct art unit suggests a consistent technical focus, even as the work is divided among different individuals.
The busiest examiner identified in the data is MISHRA, DEEPA, who accounts for 1 pending office action. With 2 distinct examiners managing the 2 pending office actions, the portfolio experiences a high degree of examiner variety relative to its size. This distribution requires the applicant to adapt to the specific preferences of different examiners within the same art unit.
The strategy for the Biotechnology & Pharmaceuticals portfolio must account for the 2 distinct examiners involved. While the 1 distinct art unit provides a stable procedural baseline, the individual interpretations of the examiners may vary. Success in these 2 pending office actions will depend on the ability to maintain a cohesive narrative while addressing the unique concerns raised by MISHRA, DEEPA and the other assigned examiner.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MISHRA, DEEPA | 1 | 28.2% | +36.1% |
| BREEN, KIMBERLY CATHERINE | 1 | 23.8% | +56.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17064826 | INDIGENOUS AND IMPROVED FUNGALLY FERMENTED CBD, CBG AND RELATED CANNABINOID ORAL DOSAGE FORMS | MISHRA, DEEPA | 119d overdue |
| 16839343 | Indigenous and Improved Bacterially Fermented CBD, CBG and Related Cannabinoid Oral Dosage Forms | BREEN, KIMBERLY CATHERINE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17064826 | INDIGENOUS AND IMPROVED FUNGALLY FERMENTED CBD, CBG AND RELATED CANNABINOID ORAL DOSAGE FORMS | MISHRA, DEEPA | 119d overdue |
| 16839343 | Indigenous and Improved Bacterially Fermented CBD, CBG and Related Cannabinoid Oral Dosage Forms | BREEN, KIMBERLY CATHERINE | — |
| Art Unit | Apps |
|---|---|
| 1657 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17064826 | INDIGENOUS AND IMPROVED FUNGALLY FERMENTED CBD, CBG AND RELATED CANNABINOID ORAL DOSAGE FORMS | MISHRA, DEEPA | 1657 | §101§103DP | Non-Final OA | 119d overdue | Pending | Oct 07, 2020 |
| 16839343 | Indigenous and Improved Bacterially Fermented CBD, CBG and Related Cannabinoid Oral Dosage Forms | BREEN, KIMBERLY CATHERINE | 1657 | §101§103§112DP | Non-Final OA | — | Pending | Apr 03, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialByo Holdings LLC has 2 pending office actions as of November 2026, spread across 1 art units and 2 examiners.
Deepa Mishra has the most, with 1 of Byo Holdings LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.